Gisens Biotech is doing for kidney disease what continuous glucose monitors did for diabetes — replacing periodic lab snapshots with real-time, non-invasive biomarker monitoring powered by nanobiosensors and AI. They serve health systems, nephrology and cardiology practices, and value-based care organizations managing patients with Chronic Kidney Disease and Cardiovascular-Kidney-Metabolic syndrome.